Skip to main content
Clinical Trials/NCT01173315
NCT01173315CompletedPhase 2

The Impact of Vitamins and Minerals Supplementation on Neuropathy and Nephropathy Complications in Type 2 Diabetic Patients: a Randomised Clinical Trial

Shahid Beheshti University of Medical Sciences0 sites75 target enrollmentStarted: June 2007Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
75
Primary Endpoint
Evidence of clinically neuropathy confirmed by nerve conduction velocities

Study Overview

Brief Summary

The combination of vitamin and mineral supplementation may improve:

  • glycemic control
  • lipid profile
  • oxidative stress
  • blood pressure
  • nephropathy indices
  • neuropathy indices

Detailed Description

A total of 75 diabetic patients (39 men and 36 women), aged 36 to 69 years, having diabetes for at least 3 years, was recruited for this study. Type 2 diabetes was defined as fasting plasma glucose 126 mg/dl (two times repeated) or taking oral glucose-lowering agents.Diabetic patients were stratified by sex and randomly assigned to one of the three treatment groups using block randomization procedure. Depending upon the treatment groups, each subject received two capsules per day, 1 with breakfast and 1 with dinner, for a period of 4 months. Each capsule contained one of the following preparations and hence determined the corresponding groups: Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo). All of the study medications, including the placebo, were supplied by Pharmaceutical Sciences Research Center (Tehran University of Medical Sciences, Iran) and were indistinguishable from each other. They were stored at 20-25 0C.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
30 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Type 2 diabetes for 3 years

Exclusion Criteria

  • Resting blood pressure >160/100 mmHg
  • Taking vitamin and/or mineral supplement, thyroid hormones, estrogens, progesterone, diuretics or antihypertensive agents
  • Having history of myocardial infarction and hepatic disease

Outcomes

Primary Outcomes

Evidence of clinically neuropathy confirmed by nerve conduction velocities

Time Frame: 4 months

nerve conduction velocities in the bilateral sural sensory nerves, and peroneal, tibial, median, and ulnar motor nerves with F waves in hands and legs extremity

Secondary Outcomes

  • nephropathy indices were determined by 3 times urine microalbumin concentration using Enzyme Immuno Assay commercial kit(4 months)

Investigators

Similar Trials